BiotechTube

Pembrolizumab + Vismodegib

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skin Basal Cell Carcinoma

Conditions

Skin Basal Cell Carcinoma

Trial Timeline

Feb 1, 2016 → Aug 29, 2018

NCT ID
NCT02690948

About Pembrolizumab + Vismodegib

Pembrolizumab + Vismodegib is a phase 1/2 stage product being developed by Merck for Skin Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02690948. Target conditions include Skin Basal Cell Carcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02690948Phase 1/2Completed

Competing Products

20 competing products in Skin Basal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
33
LY3041658 + PlaceboEli LillyPhase 1
33
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
33
levofloxacinJohnson & JohnsonPhase 2/3
65
Moisturizer A, F#9155-005Johnson & JohnsonPre-clinical
23
levofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
LevofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Levodopa-carbidopa intestinal gelAbbViePhase 3
77
IressaAstraZenecaPhase 2
52
Daptomycin + VancomycinAstraZenecaPhase 3
77
SarizotanMerckPre-clinical
23
Pembrolizumab + EDP1503MerckPhase 2
52
testosterone gel + Comparator: placeboMerckPhase 1
33
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
65
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85